Brian D. Weiss, MD
Appointment
Research Assistant Professor of Pediatrics
Email
brian.weiss@cchmc.org
Phone
513-636-9863
Fax
513-636-3549
Credentials
MD: Northwestern University Medical School, Chicago, IL, 1993
Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997
Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000
Certification
National Medical Board, 1994
Pediatrics, 1996, 2002
Pediatric Hematology-Onoclogy, 2000, 2007
Awards and Honors
- Frank A. Campini Research Fellow
- Patriot Award, US Armed Forces
- Intern teaching Award
- Editor-in-chief, Northwestern University Medical Center Literary Journal
Research
Principal Investigator for:
- NF Consortium Study 102: mTOR Inhibitors for NF-Related Plexiform Neurofibromas
- ANBL07P1: A COG Pilot Study of Intensive Induction Therapy and 131I-MIBG with Myeloablative Carboplatin, Etoposide and Melphalan (CEM) for Newly Diagnosed High-Risk Neuroblastoma
Vice-Chair for:
- N2007-01: A NANT Phase 1 Study of Ultratrace Iobenguane I 131 in Patients with Relapsed / Refractory High-Risk Neuroblastoma
- A COG Study of Sorafenib and Low Dose Chemotherapy in Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia (JMML)
Publications, Most Recent
Connect to Brian Weiss' publications on PubMed
Wagner LM, McLendon RE, Yoon KJ, Weiss B, Billups C, and Danks M: Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res 13:5418-25, 2007
Geiger H, Schleimer D, Nattamai KJ, Dannenmann S, Davies SM, Weiss B. Mutagenic Potential of Temozolomide in Bone Marrow Cells In Vivo. Blood 107(7): 3010-1, 2006.
Weiss B and Shannon K. Preliminary Examples of Preclinical Trials, in Mouse Models of Cancer, ed. Eric Holland. Wiley-Liss, 2004.
Presentations, Most Recent
- International JMML Symposium, December 2007
- NF Consortium, November 2007
- Children's Oncology Group, October 2007
- Society of Nuclear Medicine, June 2007
- NF Consortium, June 2007
- Akron Children's Hospital, May 2007
- Children's Oncology Group, October 2006
- American Society of Hematology, December 2005
- Children's Oncology Group, October 2005
- St. Elizabeth's Hospital, January 2005
Professional Organization Memberships
- American Society of Hematology
- American Society of Clinical Oncology
- American Society of Pediatric Hematology/Oncology
- International JMML Foundation, Medical Advisory Board Member
- COG High-Risk Neuroblastoma Task Force
- Children's Oncology Group-member
Special Interests
- Targeted Agents for Neurofibromatosis Type 1-Related Malignancies (including plexiform neurofibromas, optic pathway gliomas, and Juvenile Myelomonocytic Leukemia)
- High-risk neuroblastoma and I131-MIBG Treatment for treatment of Neuroblastoma
- Molecular Investigations of Cyclophosphamide-Induced Myeloid Leukemia (t-AML/t-MDS)
- New Approaches to Targeting and Killing Neuroblastoma Cells
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
